Organization Profile

You just read:

OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Apr 23, 2014, 06:01 ET